Skip to main content
Clinical Trials/ACTRN12624000678594
ACTRN12624000678594
Not yet recruiting
未知

Treatment of functional gut symptoms in patients with quiescent inflammatory bowel disease and irritable bowel syndrome - A single-blinded parallel trial assessing efficacy of app-delivered gut-directed hypnotherapy versus psychoeducation

Monash University0 sites126 target enrollmentMay 28, 2024

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Monash University
Enrollment
126
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 28, 2024
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Adults patients with quiescent IBD (determined by intestinal ultrasound (IUS)), and IBS (based on Rome criteria), who are on stable IBD therapy for at least two months.

Exclusion Criteria

  • Exclusion criteria comprises patients unsuitable for IUS (e.g., obesity, predominant rectal disease), active IBD, coeliac disease, new IBS therapies for the prior four weeks, including change in diet, supplementary probiotics, prebiotics or any medication unrelated to IBD treatment, that might influence GI function, rectal disease with constipation, pregnancy or breastfeeding, ineligibility for Medicare or inability to speak or read English or give informed consent.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
A Treatment Protocol for Patients with Gastrointestinal Stromal Tumor who are Ineligible for Participation in Other SU011248 Protocols AND are Refractory to or Intolerant of Imatinib Mesylate.Gastro-intestinal Stromal TumorsMedDRA version: 14.1Level: PTClassification code 10051066Term: Gastrointestinal stromal tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2004-001860-27-ITPFIZER1,098
Completed
Not Applicable
Medicinal treatment on symptoms in patients with gastroesophageal reflux disease (GERD) refractory to PPIs. Multicenter, randomized, paralleled controlled studyGastroesophageal reflux disease (GERD)
JPRN-UMIN000003716Department of Internal Medicine, Saga University Hospital120
Not yet recruiting
Not Applicable
Functional Gastrointestinal Disorders: Design and evaluation of an algorithm-based approach to triage, diagnosis and management.Functional Gastrointestinal DisordersOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
ACTRN12614000602628The University of Adelaide150
Active, not recruiting
Not Applicable
A TREATMENT PROTOCOL FOR PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS AND ARE REFRACTORY TO OR INTOLERANT OF IMATINIB MESYLATEPatients with Gastrointestinal Stromal Tumor who are Refractory to Standard Therapy and May Derive Benefit for Treatment with SU011248MedDRA version: 7.1Level: LLYClassification code 10062427
EUCTR2004-001860-27-FIPfizer Oy1,500
Active, not recruiting
Phase 1
A TREATMENT PROTOCOL FOR PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS AND ARE REFRACTORY TO OR INTOLERANT OF IMATINIB MESYLATEPatients with Gastrointestinal Stromal Tumor who are Refractory to Standard Therapy and May Derive Benefit for Treatment with SU011248MedDRA version: 7.1 Level: LLY Classification code 10062427
EUCTR2004-001860-27-GBPfizer Limited1,500